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Objective: To assess humoral immune response to  subunit trivalent influenza vaccine in  children suffering from 
hemophilia who had been immunized for the first time in  1993-94 and then in 1996-97. 
Methods: In autumn 1996-97, 38 previously vaccinated hemophiliac patients were subcutaneously immunized with a 
single 0.5-mL dose of subunit influenza vaccine containing the following three virus strains: A/Singapore/6/86 (HINI), 
A/Wuhan/359/95 (H3N2) and B/Beijing/184/93 (HB). Antibody response to  influenza vaccine was measured before 
vaccination, 3 weeks after vaccination and 6 months after vaccination, by use of hemagglutinin- and neuraminidase- 
inhibition tests. To present the level of seroconversion, geometric mean titers of anti-influenza antibodies, mean fold 
increase, protection rate and conversion rate were determined. All results were compared with the control group of 23 
healthy persons who had never been vaccinated against influenza and for whom the same serologic tests were carried 
out as for the vaccinated group. 
Results: Three weeks after immunization, antihemagglutinin antibody levels were 3.9-10.9 times higher than before 
vaccination, but the highest mean fold increase values were recorded 6 months after vaccination, ranging from 8.4 to  
28.6. In the case of neuraminidase, mean fold increases of antibodies reached values of 3.6-12.3 three weeks after 
vaccination and 7.1-29.1 six months after vaccination. The highest proportion of subjects protected was observed 6 
months after immunization and ranged from 76.3% to  97.4%, compared to  52.6-60.5% 3 weeks after vaccination. Similar 
values were obtained for conversion rate: 71.1-86.8% 6 months after vaccination, in comparison with 39.5-42.1% 3 weeks 
after immunization. 
Conclusions: All data obtained in  the present study indicate a significant immune response to subunit trivalent 
influenza vaccine in patients suffering from hemophilia; this is additionally confirmed by the fact that none of the 
vaccinated children were infected with the influenza virus and no serious adverse reactions were observed after 
administration of the vaccine. 
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tions, including primary influenza pneumonia or 
secondary bacterial pneumonia. Most complications 
occur among elderly persons and patients with under- 
lying medical conditions, i.e. persons with chronic 
disorders of the pulmonary or cardiovascular system or 
with metabolic diseases such as diabetes, renal dysfunc- 
tion, hemoglobinopathies and immunosuppression 
[l-31. These belong to high-risk groups and for this 
reason they should be vaccinated against influenza 
every year. Contrary to certain opinions, it has been 
shown that influenza vaccination in high-risk patients 
is effective [4-13]. It appears to prevent infection with 
the influenza virus or a t  least to decrease the severity of 
the disease. Many patients from high-risk groups and 
also healthy people are convinced that immunization is 
ineffective and wrongly think that influenza vaccine 
prevents not only influenza infections but also those 
caused by other respiratory viruses and bacteria 
[ 14-1 71. For the above reasons, we decided to assess the 
antibody response to influenza vaccine in children 
suffering from hemophilia. We considered that it would 
be interesting and useful to study the immunogenicity 
of influenza vaccine in these patients, who can also be 
considered to constitute a high-risk group, especially 
because of immunologic disorders of cellular and 
humoral components observed in this group [18-211. 
M ETH 0 D S 
Thirty-eight hemophiliac patients aged 10-19 who had 
been immunized with a single 0.5-mL dose of subunit 
trivalent influenza vaccine in 1993-94 received the 
same kind of influenza vaccine (subunit trivalent) for 
the second time in the epidemic season 1996-97. 
Each 0.5-niL dose of subunit trivalent influenza vaccine 
(Influvac, Solvay Duphar, The Netherlands) used in 
the present study consisted of 15 pg hemagglutinin of 
each of the following virus strains: A/Singapore/6/86 
(HlNl) ,  A/Wuhan/359/95 (H3N2) and B/Beijing/ 
184/93 (HB). Subcutaneous vaccination necessary to 
prevent bleeding was carried out in the Department 
of Pediatric Hematology and Oncology, Medical 
Academy, Warsaw. Huinoral immune response levels to 
hemagglutinin and neuraminidase glycoproteins were 
determined in sera collected before vaccination, and 3 
weeks and 6 months after vaccination. All samples were 
frozen at -20°C until use, and then incubated in a 
56°C water-bath for 30 min and treated with RDE 
(receptor-destroying enzyme from Vibrio cholerae) to 
remove inhibitors of hemagglutination. The hemag- 
glutinin-inhibition test and neuraminidase-inhibition 
test were carried out to measure anti-influenza anti- 
body production before vaccination, and 3 weeks and 
6 months after vaccination. The first test was done 
according to W H O  recom~nendatioiis, and for the 
second one we used Aymard-Henry’s method (a 
modification of Douglas) [22,23]. The following 
serologic parameters were deter-mned: 
geometric mean titer (GMT) of antihemagglutinin 
(HI) and antineuraininidase (NI) antibodies before 
vaccination, and 3 weeks and 6 months after vaccina- 
tion; 
mean fold increase (MFI) of HI and NI antibody 
titers 3 weeks and 6 months after vaccination [4]; 
For hunioral immune response to hemagglutinin, the 
following additional parameters were used: 
protection rate, i.e. the proportion of subjects with 
HI antibody titers 21:40; 
conversion rate, i.e. the proportion of subjects 
showing an at least four-fold increase of HI antibody 
titer after vaccination [4]. 
All results were compared with a control group of 23 
healthy persons aged 8-15 who had never been 
vaccinated against influenza and for whom the same 
serologic tests were carried out. The same serologic 
parameters as for immunized children were used, and 
the approval of the Ethical Committee, Medical 
Academy, Warsaw was obtained for this study. 
For statistical analysis we used the Mann-Whitney 
non-parametric test and paired t-test in the GraphPAD 
InStat computer program (Version 1.10). 
RESULTS 
In comparison with the results obtained before influ- 
enza vaccination, all data received for sera collected 
after immunization indicate that subunit trivalent 
vaccine is immunogenic and efficient in children with 
hemophilia. GMTs of HI as well as NI antibodies 
determined before the study were very low and ranged 
from 2.7 to 9.0 and from 2.7 to 4.0 respectively (Tables 
1 and 2). In the case of hemagglutinin, GMTs of 
antibodies after 3 weeks reached 28.3 for hemag- 
glutinin HI,  29.3 for hemagglutinin H3  and 35.2 for 
hemagglutinin HB. This means that 3 weeks after 
immunization, HI antibody levels increased 6.7-fold 
for HI,  10.9-fold for H3 and 3.9-fold for HB, while 6 
months after vaccination they increased 10.9-, 28.6- 
and 8.4-fold respectively (Table 1). In the case of NI 
antibodies, the mean fold increase in their titers was also 
higher 6 months after vaccination. It amounted to 7.1 
for neuraminidase N1, 21.3 for neuraininidase N2, and 
29.1 for neuraminidase NB, when compared with 
values obtained after 3 weeks, which were 3.6, 6.5 and 
12.3 for the same antigens (Table 2). All these 
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differences between the GMTs of HI and NI antibodies 
before and after immunization were significant within 
the vaccinated group and when compared with the 
control group (p<0.05). In order to estimate the 
effectiveness of influenza vaccine in preventing in- 
fection, the protection rate needs to be determined, i.e. 
the proportion of subjects with HI antibody titer 
21:40, which is thought to be protective. Before 
vaccination, only a small proportion (2.6-7.9%) of the 
study group had HI antibody titers equal to or higher 
than 1:40 (Table 1). Three weeks after influenza 
vaccination this value increased, ranging from 52.6% to 
60.5% for all three vaccine strains. Six months after 
immunization the percentage of subjects protected 
appeared to be much higher, amounting to 76.3% for 
hemagglutinin H1, 92.1% for hemagglutinin H3, and 
97.4% for hemagglutinin HB. Conversion rate is 
another serologic parameter which shows the level of 
humoral immune response to hemagglutinin glyco- 
protein of influenza vaccine in the present study. 
Similarly, the highest values of conversion rate were 
recorded 6 months after immunization. During this 
time they reached 71.1% for hemagglutinin H1, 84.2% 
for hemagglutinin H3, and 86.8% for hemagglutinin 
HB, compared to 42.1% for hemagglutinin H1 and H3 
and 39.5% for hemagglutinin HB 3 weeks after 
vaccination (Table 1). 
DISCUSSION 
Every year, many people from all age groups are 
infected with the influenza virus [24,25]. Some of them 
recover without any complications, but others have to 
stay under medical control for much longer, due to 
illnesses such as pneumonia or myocarditis. This is 
probably because, in spite of the availability of vaccines 
against influenza, only a small percentage of the 
population decides to be vaccinated. These people 
believe that influenza vaccine is not effective and they 
do not know about the benefits of vaccination against 
influenza [3,16,17]. Moreover, they are not aware of 
the risk connected with infections caused by this virus. 
Until influenza vaccinations are made compulsory, at 
least for high-risk groups, the number of influenza cases 
in Poland will probably not significantly decrease. 
Currently, WHO experts and those from the Advisory 
Committee on Immunization Practices recommend 
influenza vaccinations for high-risk groups, including 
patients suffering from hemophilia [2]. The results 
obtained in the present study confirm the efficacy of 
subunit influenza vaccine in hemophiliacs. This is 
evident when analyzing GMTs of HI and NI antibodies 
before vaccination and after administration of the 
vaccine. The mean fold increase levels showed that, 
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Table 2 NI antibody kinetics in previously vaccinated children suffering from hemophilia who were immunized against 
influenza in the epidemic season 1996-97 
GMT of NI antibodies. Mean fold increase 
After vaccination After vaccination Before 
Antigen Group vaccination 3 weeks 6 months 3 weeks 6 months 
AiSingapore/h/86 Vaccinated 4.0 14.4 28.3 3.6 7.1 
(HI N1) Control 1.1 3.0 6.8 2.7 6.3 
AiWuhan/359/95 Vaccinated 3.3 21.5 70.4 h i 21.3 
(H3N2) Control 1.2 4.6 8.7 3.8 7.3 
B/Beijing/84/93 Vaccinated 2.7 33.3 78.6 12.3 29.1 
(HB) Control 1.2 6.1 11.2 5.1 9.3 
GMT, geometric mean titer. 
Vaccinated group: t1=38. 
Control group: n=23. 
6 months after immunization, anti-influenza antibody 
titers reached values which were 8.4-28.6 times higher 
for the hemagglutinin component than before the 
study, and 7.1-29.1 times higher in the case of 
neuraminidase glycoprotein. In the control group, 
GMTs of HI and NI  antibodies also increased after 6 
months in comparison with the values recorded before 
the study and after 3 weeks, although these children 
were not vaccinated. This is especially evident in the 
case of hemagglutinin HB, where after 6 months the 
mean fold increase was 12.1 and the protection rate and 
conversion rate amounted to 30.4%. The above obser- 
vation could be explained by persons from the control 
group being infected with the influenza virus during 
the study. 
All hemophiliac children involved in the present 
study had previously been vaccinated against influenza 
in the epidemic season 1993-94, so immunization in 
autumn 1996-97 was their second vaccination. In spite 
of this fact, the humoral immune response to influenza 
vaccine observed in these patients did not weaken, as 
many authors suggest [26-291. This is clearly seen 
when the results of this study are compared with 
data obtained in our previous investigation on sero- 
conversion in once-immunized hemophiliac children 
[30]. In the case of children vaccinated in 1993-94 and 
then in 1996-97, the proportion of subjects protected 
6 months after influenza vaccination ranged from 
76.3% to 97.4%, while in hemophiliac patients 
immunized only in 1993-94 it was almost the same, 
i.e. 75%-94% [301. These similar values could be 
explained by the facts that three epidemic seasons 
elapsed between the first vaccination and the second, 
and that different antigens were used in the epidemic 
seasons 1993-94 and 1996-97. Obviously, much 
depends on the anti-influenza antibody titer deter- 
mined before vaccination, which was significantly 
higher in patients immunized only once (epidemic 
season 1993-94) than in patients immunized twice 
(epidemic seasons 1993-94 and 1996-97) [26,28]. This 
fact indicates that children in the epidemic season 
1993-94 must have had contact with the influenza 
virus before their immunization in comparison with 
children in the epidemic season 1996-97. It could be 
expected that immune response levels to influenza 
vaccine would be lower in patients suffering from 
hemophilia, because of certain immunologic abnor- 
malities observed in these patients. These immunologic 
disorders can be related to both cellular and humoral 
components and are probably connected with trans- 
fusion of blood product preparations [20-231. Never- 
theless, it appears that subunit trivalent influenza 
vaccine is immunogenic in children with hemophilia 
and induces anti-influenza antibody production to an 
extent which is sufficient to protect against infection 
with the influenza virus [30,31]. The number of cases 
of influenza and influenza-like illness registered in 
Poland in the epidemic season 1996-97, i.e. from 
1 October 1996 to 30 April 1997, amounted to 
1 575 460, with an incidence per 100 000 of 4076.2. 
Additionally, the Warsaw region, where this study was 
carried out, was one of those with the highest activity 
of influenza in 1996-97 in Poland. Considering the 
above facts. it must be stressed that none of the 
hemophiliac children had suffered from an influenza- 
like disease during the 6 months following the 
revaccination against influenza, and no serious adverse 
reactions after administration of the vaccine were 
observed, in spite of subcutaneous vaccination. 
CONCLUSIONS 
From serologic results obtained in the present study, we 
can conclude that immunization with subunit trivalent 
influenza vaccine in previously vaccinated patients 
suffering from hemophilia seems to be efficient and to 
prevent infections caused by the influenza virus. This is 
confirmed by the fact that no cases of influenza-like 
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disease were observed in the vaccinated patients, while 
in the control group four cases of influenza were 
hagnosed. The immunogenicity of influenza vaccine 
was confirmed, in spite of the fBct that children were 
suffering from hemophilia, a serious metabolic dis- 
order, and had previously been immunized against 
influenza once. Moreover, the vaccine was admini- 
stered subcutaneously in all cases. We hope that the 
clinical data presented in this paper, as well as those of 
other authors, will contribute to an increased awareness 
of the efficacy of immunization against influenza 
among physicians, and that they will promote the idea 
of influenza vaccination among their patients. 
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